We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
- Authors
Keedy, Vicki Leigh; Temin, Sarah; Somerfield, Mark R; Beasley, Mary Beth; Johnson, David H; McShane, Lisa M; Milton, Daniel T; Strawn, John R; Wakelee, Heather A; Giaccone, Giuseppe
- Abstract
An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This PCO addresses the clinical utility of using epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer (NSCLC) to predict the benefit of taking a first-line EGFR tyrosine kinase inhibitor (TKI).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 15, p2121
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.31.8923